Identify potential early,
partner aggressively,
think globally

Anna French Ph.D. is a Principal at Qiming Venture Partners USA, based in Cambridge, MA. Prior to joining Qiming in 2017, Dr. French was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused on cell therapy commercialization. Dr. French earned a D.Phil from the University of Oxford, UK where her research focused on hematological differentiation of human induced pluripotent stem (iPS) cells. She has over 20 publications in the field of stem cell research.

QM US portfolio: Anna serves on the board of WindMIL Therapeutics and is a board observer with Let’s Get Checked, Talaris Therapeutics and Platelet Biogenesis.

Christopher Shen MD, is a Managing Partner at Qiming Venture Partners USA, based in Los Altos, CA. Prior to joining Qiming, Dr. Shen was a Managing Director and head of U.S. healthcare investing at Vertex Ventures Healthcare. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. He has worked with seven companies that have since gone public or been successfully acquired, worth over US$2.1 billion in value. Notable past investments include Twelve (acquired by Medtronic), Entellus Medical (acquired by Stryker), Nellix Endovascular (acquired by ELGX), Bridgepoint Medical (acquired by BSC), Evalve (acquired by Abbott), Glycomimetics (IPO), Ivantis, and Moximed.

Previously, Dr. Shen worked at Essex Woodlands, a healthcare-focused venture capital and private equity firm. Prior to joining Essex, he worked at New Enterprise Associates, one of the largest diversified venture capital firms. Previously, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation’s Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer Inc.’s Strategic Innovation Group, an internal medical technology incubator.

Dr. Shen is the US Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He is also an Adjunct Professor at Stanford Business School. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.

Dr. Shen received his MD, MBA, MS in Biomechanical Engineering and BS in Biological Sciences all from Stanford University.

QM US portfolio: Chris serves on the board of Cardialen and Nuvaira 

Colin Walsh Ph.D. is a Principal at Qiming Venture Partners USA, based in Los Altos, CA. Before joining Qiming in April 2019, Dr. Walsh was a Vice President on the life science investment team at NanoDimension where he sourced, structured, and managed investments in biotech, biopharma, and platform companies.  Prior to NanoDimension, Dr. Walsh was an early employee at Precision NanoSystems (PNI), a 5AM Ventures backed biotech startup developing a suite of technologies to enable the development and manufacture of complex drug formulations. At PNI, he focused extensively on RNA- and DNA- based therapeutics, and held a variety of product and business development roles where he worked closely with management to define the strategy and direction of the business.

Dr. Walsh earned a Ph.D. from the UC Berkeley – UCSF Graduate Program in Bioengineering where he worked on novel delivery systems for RNA-based therapeutics as an NSF Graduate Research Fellow in the lab of Dr. Frank Szoka. He holds a Management of Technology certificate from the UC Berkeley Haas School of Business, and a dual BS with Honors in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst.

Dr. Walsh currently serves on the business advisory board for the Harvard Medical School Initiative for RNA Medicine. He is also an advisor to the Stanford SPARK program and the UCSF Catalyst program where he provides mentorship and support to student- and faculty-led translational research projects.

Gary Rieschel has over 35 years of successful operating and investing experience as a senior executive, entrepreneur, investor, and global business strategist. Mr. Rieschel has held executive positions at Intel, Sequent Computer, Cisco Systems, and Softbank Corporation. Over the last 20 years as a venture capitalist, he led investments in 13 companies in the U.S. and China which grew to over $1B USD in market capitalization. Gary aided in the creation of the venture capital industry in China through sponsoring and founding several of China’s leading VC firms including Softbank China Ventures, SAIF Partners (2001), Ceyuan Ventures (2004), and Qiming Venture Partners (2006). He is Founding Managing Partner of Qiming, one of China’s preeminent VC firms with over $4.3B under management. In 2016, Gary returned to the U.S. after 12 years in China and launched Qiming’s first operation in the U.S. which now has over $300M USD under management invested in cutting edge healthcare investments. He remains on Qiming’s Executive and Investment Committees and represents Qiming on the board of Lanzatech, a leading environmental biotech company.

Mr. Rieschel is well regarded as a mentor to entrepreneurs, founders, and other venture capitalists. He is on the board of many preeminent environmental organizations including The Nature Conservancy (Montana), PERC (Free Market Environmentalism), the Climate Leadership Council, the Asia Society (Advisor) and he helped introduce the Rocky Mountain Institute into China.   Gary also serves on the board of the U.S. Olympic Foundation and is a permanent member of the Council on Foreign Relations. He attended Reed College (Biology) where he is a long time Trustee, and Harvard Business School.

Mr. Rieschel now lives in Seattle, WA.

Gary holds a BA in Biology from Reed College in Portland, OR, and an MBA from the Harvard Business School. He lived in Japan for five years in the late 1980s and lived in Shanghai from 2005 through 2016. He now lives in Seattle, WA.

QM US portfolio: Gary serves on the board of Madaket Health

Mark Bonyhadi Ph.D. is an Operating Partner at Qiming Venture Partners USA, based in Seattle, WA. Prior to joining Qiming USA in December of 2018, Dr. Bonyhadi held positions of Vice President of Research, Head of Academic Affairs, and Vice President of Process Research Sciences from 2013-2018 at Juno Therapeutics, Inc., which was recently acquired by Celgene Corporation.

From 2006-2013, Mark was Director of Global Business Development for Cell Therapy at Invitrogen, which was merged with Applied BioSystems, to create Life Technologies, which subsequently was acquired by Thermo-Fisher.  Dr. Bonyhadi was responsible for identifying and implementing business opportunities aligned with the Lifetech/Invitrogen/Thermo cellular medicine portfolio, participating and leading in the launch of the Cell Therapy Systems (CTS™) product line optimized for cell therapy applications, as well as working with academia and industry to accelerate the development of novel cell and/or gene-based therapies.

From 1997-2005, Dr. Bonyhadi served as Director and later Vice President of Research at Xycte Therapies, a public Seattle-based T cell therapy company treating cancer, infectious disease and autoimmunity.

Before heading to Xcyte, Mark spent from 1990-1997 working his way up to a Senior Scientist level at SyStemix, a public Palo Alto-based biotech company developing hematopoietic stem cell based therapies for treating cancer, as well as gene-therapy approaches for treating HIV infection.  The latter was a collaborative effort with Sandoz, which later merged with Ciba Geigy to become Novartis.  Dr. Bonyhadi did his Postdoctoral training at SyStemix with Drs. Mike McCune and Hideto Kaneshima studying HIV pathogenesis in the SCID-hu mouse model.

Mark is Chair of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (ASGCT).   Mark received a B.A. from Reed College, Portland, OR and a Ph.D. from UC Berkeley in the lab a James P. Allison, where he studied T cell immunology.

Since graduating from UC Berkeley, Dr. Bonyhadi has been focused on the development of commercially viable approaches for bringing cell therapies, gene-modified cell therapies, and regenerative medicine from the bench, to the clinic, and into commercial use over the past three decades.  Dr. Bonyhadi currently lives in Seattle, WA.

Mark McDade, is a Managing Partner at Qiming Venture Partners USA, based in Cambridge, MA. Before joining Qiming in 2017, Mr. McDade was Executive Vice President, Chief Operating Officer at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development. He joined UCB’s Executive Committee in 2008.

From 2002 until late 2007, Mr. McDade served as Chief Executive Officer and a director of PDL Biopharma, an antibody-based biopharma located in Redwood City, CA, USA. Prior to PDL, he served as CEO of Signature Bioscience, located in San Francisco, CA. Mark was founder and a director of Corixa Corporation, where he served as Chief Operating Officer from September 1994 to December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000 to join Signature. Before Corixa, Mark was COO of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange, and prior to that held several positions at Sandoz Ltd. Including business development, product management and general management.

Mr. McDade serves on the Board of directors of FivePrime Therapeutics (FPRX), Dermira (DERM) and Aimmune Therapeutics (AIMT), all publicly traded biotechs in the SF Bay Area. Mark received a BA from Dartmouth College and an MBA from the Harvard Business School.

QM US portfolio: Mark serves on the boards of Cadent Therapeutics, Let’s Get Checked, myHealthteams, Platelet Biogenesis, WindMIL Therapeutics and ZappRx. He led our investments in Kezar Life Sciences (KZR) and Twine Health (acquired by FitBit (FIT)).